Page 76 - MEMOCiberes014-ENG

RESEARCH GROUPS
Group 9
Programme: Tuberculosis (TB)/ Host-Pathogen Interactions
Lead Researcher: Martín Montañés, Carlos Group members
STAFF MEMBERS: Cebollada Solanas, Alberto | Lampreave Carrillo, Carlos
ASSOCIATED MEMBERS: Aguiló Anento, Ignacio | Ainsa Claver, José Antonio | Alonso Ezcurra, María He- nar | Arbues Arribas, Ainhoa | Dias Rodrigues, Liliana Isabel | Gavin Benavent, Patricia | Gómez Aguirre, Ana Belen | Gómez Lus, Rafael | Gonzalo Asensio, Jesús | Gracia Díaz, Begoña | Ibarz Bosqued, Daniel | Iglesias Gozalo, María José | Lafoz Pueyo, Carmen | Lezcano Carrera, María Antonia | Lucía Quintana, Ainhoa | Millán Lou, María Isabel | Otal Gil, Isabel | Pico Marco, Ana | Revillo Pinilla, María José | Rubio Calvo, María Carmen | Samper Blasco, Sofía Luisa | Solans Bernad, Luis | Villellas Arilla, María Cristina | Vitoria Agreda, Ma Asunción
Main lines of research
Our Research Group of Mycobacterial Genetics has been working since 1992 in four lines of research fi- nanced by European and national investigation funds and that has permitted it to acquire an internationally recognized prestige. These lines of research include: Construction of New Vaccines against Tuberculosis • Molecular Epidemiology of Tuberculosis & Transposition and Latency of M. tuberculosis • Molecular Bases of the Resistance of mycobacteria .
The objectives of our group are to study the complexity of M . tuberculosis in a multidisciplinary focus and our group is coordinated with other national and international groups . More concretely we focus our re- search in: Genes implicated in the pathogenicity and virulence of M. tuberculosis • Molecular epidemiology of tuberculosis, risk factors of transmission, and differences between strains of major epidemiological im- portance and the mechanism of slow growth of the Koch bacillus • Mechanisms of resistance.
Active Projects:
• Line 1: NEW TBVAC 241745 FP7 Discovery and preclinical testing of new vaccine candidates for tu- berculosis . European Union Organization . Chief Researcher and Coordinator: Carlos Martín Montañes “http://www.tbvi.eu/projects/newtbvac.html/ 2010- 2014 Coordinator Dr Jelle Thole NL. • BIO2011- 23555 BIO2011-23555 Project: “Study of the mechanisms of protection of MTBVAC and its potential use as recombinant polyvalent vaccine .” MCyT/DGI/FEDER Organization . 2012-2014 . Chief Researcher and Coordinator: Carlos Martín • INNPACTO: Ref. IPT-2012-0327-090000 Ministerio de Economía y Competitividad “Vacuna Inactivada contra la tuberculosis en base a una cepa modificada genéticamen- te – .Universidad de Zaragoza, IP: Carlos Martín, Universidad Complutense y la empresa BIOFABRI .
• Line 2: Polimorfismos genómicos y transcriptómicos en M . tuberculosis complex y su significado en clínica . IP: Sofía Samper . Number of researchers: 10; FIS, Instituto de Salud Carlos III . 2013- 2015 .
76
CIBERES » Annual report 2014